Sign inJoin waitlistJoin the waitlist

Farzana Perwad

Division Chief of Nephrology · University of California (San Francisco) School of Medicine

Credentials: · · · ·

History

Nephrology Division · University of California (San Francisco) School of Medicine
Present
Division of Nephrology · UCSF Benioff Children’s Hospital Oakland
Present
University of California (San Francisco) School of Medicine
Present

Pediatric Nephrology
University of California-San Francisco
2002–2005
Pediatrics
Nicklaus Children's Hospital
1996–1999
KASTURBA MED COLL, MANIPAL, KARNATAKA
1992–1996

Research

Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice
Endocrinology · 2005 · First of 6 authors · 333 citations
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial
The Lancet · 2019 · 298 citations
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24…
Journal of Bone and Mineral Research · 2018 · 274 citations

Anthony Portale
20 papers
Erik Imel
8 papers
PP
Pisit Pitukcheewanont
8 papers
Gary Gottesman
4 papers
Jill Simmons
4 papers
Karl Insogna
4 papers
MW
Michael Whyte
4 papers
Suzanne De Beur
4 papers
Thomas Carpenter
4 papers
Tom Weber
4 papers
Bradley Warady
3 papers
Onur Cil
3 papers

Grants

Molecular Regulation of Renal 125(OH)2D Production by Fibroblast Growth Factor23
National Institute of Diabetes and Digestive and Kidney Diseases · K08
Contact PI · $621.8K · University of California, San Francisco
2006–2012

Clinical trials

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
Site PI · Recruiting · Phase 1, Phase 2
Kyowa Kirin Co., Ltd.
2024–2029
Ferric Citrate and Chronic Kidney Disease in Children
Site PI · Recruiting · Phase 2
University of California, Los Angeles
2022–2028